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ADEM Acute demyelinating encephalomyelitis 
CCM Cryptococcal meningitis 
CMV Cytomegalovirus      
HAART Highly active antiretroviral therapy 
MS Multiple sclerosis 
NMO Neuromyelitisoptica 
ON Optic Neuritis 
ONTT Optic Neuritis Treatment Trial 
TB Tuberculosis 
TM Transverse myelitis 
TNF  Tumor necrosis factor 
Toxo Toxoplasmosis 








To determine the clinical profile, causes and response to corticosteroid therapy in patients 
admitted and treated for optic neuritis at a tertiary hospital in Cape Town, South Africa. 
 
Methods 
A retrospective case review was conducted of 117 patients admitted to Groote Schuur 
Hospital and treated for optic neuritis between January 2002 and December 2012. 
Inclusion criteria were based on clinical findings of acute optic nerve dysfunction with or 
without optic disc swelling. Demographic information, clinical presentation, course of 
illness, investigations performed and visual outcomes at discharge and at three month 
follow up were collected. Data analysis was performed using STATA version 10.0.  
 
Results 
60 of 117 patients (51%) had an identifiable secondary cause for optic neuritis. Of the 57 
patients with idiopathic optic neuritis only 14 had features of “typical optic neuritis” 
associated with demyelinating disease. HIV and syphilis accounted for 62% of secondary 
causes of optic neuritis. Presenting visual acuity of hand movements (HM) or worse and 
absence of pain with extra ocular movement were associated with poorer final visual 
outcomes in the idiopathic optic neuritis group.  
 
Conclusion 
Optic neuritis in our patients, as elsewhere in Africa,tends to be atypical in presentation, 
with a high proportion of patients having an identifiable, most commonly infectious, 
cause.These patients thus require more extensive investigation in order to identify 
possible causes which may influence management.  In settings with a high HIV 
prevalence, HIV and syphilis testing should form part of the routine first line investigations 
for patients with optic neuritis.Secondary optic neuritis and idiopathic atypical optic 





























Optic neuritis is an inflammatory, infective or demyelinating process affecting the optic 
nerve.1The condition can be classified according to the segment of the optic nerve affected, 
thus it can be retrobulbar, it can affect the optic nerve head (papillitis), or it can affect the 
nerve head and retinal nerve fibre layer (neuroretinitis). Aetiologically it can be classified as 
demyelinating, parainfectious, infectious, non-infectious, or inflammatory.1 
In the U.S.A, northern Europe and Australasia, demyelinating optic neuritis is the most 
common cause of painful visual loss in young adults.2 Furthermore there is a high 
association in these regions with the systemic demyelinating condition multiple sclerosis. 
The estimated annual incidence of optic neuritis in the U.S.A is 5 per 100 000 (prevalence 
115 per 100 000) which closely follows the epidemiology of multiple sclerosis.2,3 In contrast 
multiple sclerosis is rare in Africa.4 The estimated prevalence in South Africa is 3.5 per 100 
000, being recorded predominantly in white people of European descent, though few 
isolated cases of mixed descent people have been recorded.4 The landmark prospective 
Optic Neuritis Treatment Trial (ONTT) followed up 377 cases of optic neuritis over 15years, 
uncovering valuable information in terms of the clinical risk profile for the development of 
multiple sclerosis and the response to treatment with high dose corticosteroid therapy.2,3 
The ONTT identified several clinical features with a high association with demyelinating 
disease coining the term “typical” features.2 The main features identified were age (between 
15 and 45years), pain on eye movement, no underlying systemic illness, deterioration in 
vision over a few days to two weeks, thereafter  spontaneous improvement within two to  
three weeks, and unilateral visual loss.2,5The ONTT as well as meta-analyses of 12 
randomised control trials revealed that corticosteroid therapy significantly improved short 
term visual acuity but had no statistically significant effect on long term visual outcome.2,5 
The clinical experience at Groote Schuur Hospital is that the vast majority of our patients do 
not fit the typical profile of the ONTT. Furthermore the HIV epidemic confounds the clinical 
picture both due to the neurotrophic nature of the virus and associated opportunistic 
infections. The basis for the use of corticosteroid therapy stems from the ONTT. Patients 
thus require admission for three days of intravenous corticosteroids followed by oral therapy 
as an outpatient (despite there being no evidence for long term visual benefit).2,3 
Pokroy et al looked at the clinical profile of cases of idiopathic optic neuritis in black Africans 
and their response to treatment.6 In contrast to the ONTT they found that of the 10 patients 
in their study, the majority had bilateral consecutive or simultaneous disease and 15 out of 
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the 18 eyes had optic disc swelling.6 They found that black African patients had a poorer 
visual prognosis compared to the patients in the ONTT.6 The study however excluded 
secondary causes of ON in African patients. There is little information as to the causes of 
optic neuritis in an African population. 
Storoni et al reported similar findings of atypical optic neuritis in patients of African or 
African-Carribean backgrounds.7 They further report that this group of patients has a 
disproportionately higher representation within the neuromyelitis spectrum of disorders than 
Caucasian patients in the study population.7 Several studies have further shown a high 
incidence of aquaporin-4 antibody (a marker for neuromyelitisoptica) amongst patients with 
isolated atypical optic neuritis, furthermore NMO-seropositivity was shown to be a predictor 
of poor outcome.8,9 
This study will look at all cases of optic neuritis admitted to and investigated at Groote 
Schuur Hospital. Clinical and demographic profiles of patients as well as secondary causes 
and response to treatment will be reported on. 
 
1.2 Justification 
 To describe the clinical and demographic profile of patients with optic neuritis 
attending Groote Schuur Hospital (urban African community) 
 To determine if there are any clinical or demographic features that help predict the 
course, final outcome and response to therapy 
 To determine the causes of optic neuritis in the above population 
 To determine the short term and long term visual outcome of patients affected with 
optic neuritis in the above population 
 To determine the response to steroid therapy for optic neuritis in the above 
population 
 To determine whether the above response to treatment justifies admission for and 




 What are the clinical and demographic features of optic neuritis in patients attending 
Groote Schuur Hospital? 
 What clinical or demographic features help predict the final visual outcome or the 
response to treatment with corticosteroids? 
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 What are the underlying causes of optic neuritis in this population? 




2.1 Study Design 
Type of Study – Descriptive and Analytical Retrospective case series 
 
2.2 Sample Collection 
Medical records of patients admitted to Groote Schuur Hospital Department of 
Ophthalmology with optic neuritis from the period 2002 to 2012 will be collected for analysis. 




Case records will be reviewed and the following data extracted for analysis: 




2. Clinical Information (background and presentation) 
 Known ocular disease 
 Known systemic disease 
 Unilateral or bilateral involvement 
 Pain with eye movement on presentation 
 Presenting visual acuity both eyes 
 Presenting Ishihara score both eyes 
 Brightness and contrast scores both eyes 
 Presence of relative afferent defect and grading 
 Visual fields (if able to perform) 
 Optic disc (swelling present or absent) 
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3. Investigations done and diagnosis if underlying cause present 
 - CT scan (positive or negative findings) 
 - MRI findings (positive or negative for plaques suggestive of multiple sclerosis) 
 - Blood investigations (autoimmune markers, serum ACE, ESR, FBC, HIV, VDRL& 
FTA) 
 - Lumbar puncture (positive or negative findings) 
 - Secondary diagnosis if applicable 
 
4. Follow up & Response to Treatment 
 Visual acuity, Ishihara score & brightness appreciation  
- at discharge (after three days of intravenous methylprednisilone) 
 - at first follow-up and time of first follow up (weeks – months) 
 - at final visit and time of last visit post onset 
 
3. Analysis 
Data will be collated on Microsoft Excel spreadsheets and analysed using STATA version 
9.0. The data will be collected as both numerical and categorical variables. Variables will be 
described, where appropriate, using means, medians and proportions. Univariate and 
multivariate analysis will be performed with appropriate statistical tests of significance (t-test 
for parametric data, Wilcoxon rank-sum for non-parametric data and Chi square or Fischers 
exact test for proportions). All statistical tests of significance will be based on a p value < 
0.05. 
The main analysis will focus on: 
1. Clinical and demographic features that predict the course and outcome of optic neuritis in 
the population sample. 
2. The response to treatment with a course of systemic steroids (three days of intravenous 
methylprednisilone followed by 11 days of oral prednisone) using visual acuity, Ishihara 
colour plate scores and subjective brightness appreciation as the measures of outcome. 
3. The proportion of cases of optic neuritis that can be attributable to a secondary cause and 




4. Ethics & Communication 
4.1 Ethics 
Ethical approval for this study will be obtained from the University of Cape Town Faculty of 
Health Sciences Ethics Committee. 
 
4.2 Reporting of Data 
A paper reporting the findings of the study will be submitted to a peer reviewed journal for 
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Optic neuritis is an inflammatory disorder of the optic nerve with multiple aetiologies1,2. In 
high income countries demyelinating disease, and more specifically multiple sclerosis, is the 
leading cause of optic nerve inflammation1,2. Multiple sclerosis (MS) predominantly affects 
female Caucasian patients1,2. The aetiology of optic neuritis in Africa, with high endemic 
rates of HIV infection and other infectious diseases, is poorly described. The objectives of 
this literature review are: 
 To determine the clinical profile of optic neuritis in African patients / population; 
 To determine the predominant aetiology of optic neuritis in African patients; 
 To determine if HIV is a cause and/or risk factor for the development of optic neuritis; 
 To determine the effect of steroid therapy for the treatment of optic neuritis in 
populations with a low multiple sclerosis incidence; 
 To identify gaps in knowledge and the need for further research. 
 
2. Literature search strategy 
The PubMed Health database was used to perform a search of relevant literature in peer 
reviewed journals. The search was conducted with the following keywords: 
Optic neuritis + multiple sclerosis, atypical, typical, neuromyelitisoptica, African population, 
HIV, treatment, ADEM. 
3. Summary and interpretation of literature 
 
3.1 Introduction 
Optic neuritis (ON) is defined as an inflammatory condition of the optic nerve1,2,3,4. The 
aetiology can be divided into demyelinating, infectious, para-infectious and non-infective 
inflammatory disorders1,2,3. The most common cause of optic neuritis worldwide is 
demyelinating disease, and in countries where multiple sclerosis is common this accounts 
for the majority of cases1,2,3,4. In the United States the incidence of optic neuritis is 
approximately 5/100 000, which closely follows the incidence of multiple sclerosis1,2,3. Optic 
neuritis is most commonly unilateral and tends to affect females more than males1,2,4. 
3.2 Optic neuritis  and demyelinating disease 
Demyelinating optic neuritis is the most common cause of unilateral, painful visual loss in 
young adults in the United States3. Most cases of optic neuritis are idiopathic but it is the 
initial manifestation of multiple sclerosis in approximately 20% of patients1,3.  
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MS is a demyelinating disease characterized by episodes of neurological fall out that are 
divided by both time and space5. There is a female preponderance with a male to female 
ratio of 1:5. Magnetic resonance imaging (MRI) on patients with MS typically shows peri-
ventricular plaques5,6. The landmark Optic Neuritis Treatment Trial (ONTT) was a multicenter 
randomized control trial with 15 year follow-up data looking at risk factors and treatment 
outcomes for MS related optic neuritis6.  389 patients were recruited and the study consisted 
of two components; the ONTT (consisting of three treatment arms) and the Longitudinal 
Optic Neuritis Study, which was a follow up of the clinical progression. The aims of the study 
were to describe the natural history of demyelinating ON, assess the benefits and risks of 
treatment with corticosteroid, and identify risk factors for the development of MS2,6. The 
ONTT identified those features which had a higher association with the development of MS 
giving rise to the term “typical optic neuritis”. The features of typical optic neuritis are 
summarized in Table 14. One of the main findings of the study was the predictive value of 
MRI abnormalities or plaques and the risk of developing MS. The 15 year data shows that 
the risk of MS with typical optic neuritis and no plaques on MRI is 25%; with one or more 
plaques this risk increases to approximately 75%6.  
Neuromyelitisoptica(NMO) is an acute inflammatory demyelinating disease affecting the 
optic nerves and spinal cord7. Episodes of demyelination tend to recur and optic nerve 
involvement may be unilateral or bilateral4,7. ON may precede or follow an episode of 
transverse myelitis7,8. The varied presentation of NMO often leads to its misdiagnosis as 
possible MS, and thus a new classification of NMO spectrum disorders was devised7. In a 
cohort of 175 patients 87% did not present with simultaneous onset bilateral ON and 
myelitis. Most presented with isolated unilateral ON, isolated bilateral ON, isolated myelitis or 
brainstem encephalitis9. More recently the serum antibody NMO-IgG has been identified and 
is found to be present in approximately 70% of cases9,10. The NMO antibody targets 
Aquaporin 4 channels and results in a cascade of events resulting in inflammation9,10,11. The 
NMO study group considers NMO-antibody testing to be the most important test in the work 
up of patients with suspected NMO10(See Table 2. Diagnostic criteria for NMO). Since the 
initial clinical presentation is varied, NMO-antibody testing helps differentiate these 
symptoms from possible MS10,11. Various groups have suggested the terms AQP4-Ab 
positive classical NMO (for patients presenting with ON and myelitis) and AQP4-Ab positive 
‘high risk syndromes for NMO’ (for isolated ON, myelitis or encephalitis)10. Recent advances 
in retinal imaging using OCThave shown that a single attack of NMO ON causes more 
damage to the retinal nerve fibre layer (RNFL) than MS12. This may account for the poorer 
visual outcome in NMO12.   
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The pathogenesis of demyelinating conditions is not well understood but is thought to be a 
result of T cell mediated (MS), or antibody mediated (NMO) inflammation of the central and 
peripheral nervous system2. The release of cytokines and other inflammatory mediators 
causes neuronal cell death, resulting in demyelination and aberrant nerve conduction2. The 
possible role of molecular mimicry inciting an autoimmune response has also been 
postulated in particular with NMO and tuberculosis13,14. MS and NMO account for most 
cases of demyelinating disease; however, there are various other described conditions with 
clinical overlap.  
Acute demyelinating encephomyelitis (ADEM) is a monophasic, multifocal demyelinating 
process which may have associated ON15. The ON is more commonly bilateral, severe and 
tends not to occur in isolation of systemic manifestations15. ADEM is often preceded by an 
immunological trigger such as a recent viral infection or vaccination15,16. It occurs more 
commonly in children and tends to occur in the winter months15. Neurological symptoms 
manifest within days of disease onset and encephalopathy is usually present early in the 
disease course15. The International Paediatric MS study group proposed diagnostic criteria 
to differentiate ADEM from MS15. The criteria include poly symptomatic neurology including 
encephalopathy, no previous evidence of demyelination and distinct radiological features15. 
There is a postulated link between HIV infection and the development of ADEM16. 
Raychaudhuri et al describe a case of the haemorrhagic variant of ADEM in a patient 
presenting with acute bilateral blindness as the presenting feature of his illness16. ADEM has 
been described both during seroconversion illness as well as late in the disease process16. 
Table 3 lists some of the differentiating features between ADEM, MS and NMO. 
 
Table 1. Typical and Atypical features of Optic Neuritis4 
Typical Optic Neuritis Atypical Optic Neuritis 
 Acute to sub-acute onset – 
progressive over a few days to two 
weeks 
 
 Young adult patient, typically less 
than 45 years of age, but may be of 
any age 
 
 Periocular pain (90%), especially with 
eye movement – preceding or 
coinciding with visual loss 
 
 Unilateral loss of visual acuity – 
variable severity 
 
 Age >50yrs or <12yrs 
 
 Absence of pain or severe pain 
 
 Severe visual loss 
 




 Bilateral involvement 
 




 Normal (65%) or swollen (35%) optic
nerve head
 Visual field defect – almost any type
 Spontaneous visual improvement in
>90% starting  within two to three
weeks regardless of treatment
 No deterioration in vision when
corticosteroids are withdrawn




+ at least two of the following
Contiguous MRI spinal cord lesion involving three or more vertebral segments 
Brain MRI non-diagnostic for MS 
NMO IgG seropositivity 
Table 3. Differentiating features between MS, NMO & ADEM  
MS NMO ADEM 































axis of ventricle 
Contiguous spinal 
cord lesions over 
three or more 
vertebral segments 
Extensive optic 
nerve and chiasmal 
lesions 
Multifocal diffuse 
white matter lesions 










3.3 Optic neuritis in African patients 
Limited information is available on the causes and outcomes of ON in African populations. 
Pokroy et al looked at the clinical profile of cases of idiopathic ON in black Africans and their 
response to treatment17. In contrast to the ONTT they found that of the 10 patients in their 
study, the majority had bilateral consecutive or simultaneous disease and 15 out of the 18 
eyes had optic disc swelling17. Black African patients also had a poorer visual prognosis 
compared to the patients in the ONTT17. The review, however, excluded secondary causes 
of ON in African patients.  
Many case reports and series describe secondary causes for ON in African patients. The 
causes include malaria, syphilis, infectious meningitis and nutritional disorders18,19,20. Several 
reports of endemic optic neuropathy have been described particularly in Eastern and Central 
African countries and are thought to be a consequence of micronutrient deficiencies. 
Plant et al report on an epidemic of optic neuropathy affecting young adults in coastal 
Tanzania20. 47% of cases had associated peripheral neuropathy. No cause was identified 
but the patients showed some clinical similarity to Strachan’s syndrome and, although not 
confirmed,it was probably due to micronutrient deficiencies20. A similar epidemic is described 
in Somalia with 105 acute cases of optic neuropathy in young adults with evidence of a 
peripheral neuropathy21. Micro-nutrient deficiencies must thus be considered in patients 
presenting with bilateral optic neuritis with associated peripheral neuropathy. A follow up 
study in Dar-es-Salaam recruited 57 cases to identify a causal agent in Tanzanian epidemic 
optic neuropathy22. They found associations between low folate status, cooking indoors 
more than twice a week on coal or wood fired stoves, and an increased risk of developing 
optic neuropathy22. 
3.4 Multiple sclerosis and neuromyelitisoptica in South African patients 
The global prevalence of MS varies between 2 and 150 / 100 00023. There are several 
studies which have tried to identify the MS rates in South Africa. Dean et al in 1967 reported 
an incidence of 13/100 000 in English speaking whites with 0 cases reported in black 
patients24. A follow up study in 1994 (using case records dating back to 1947) reported only 
sixcases of possible MS in black South Africans25. Bhigjee et al reported on crude 
prevalence data in the Kwazulu Natal province of South Africa, with a prevalence of 
25.63/100 000 in whites, 0.99/100 000 in blacks and 1.94/100 000 in people of mixed 




There is very limited information regarding the epidemiology of NMO in African countries, 
and there is also little information about global prevalence rates. The estimated prevalence 
of NMO is between 0.5 and 4.4 / 100 00027. Several clinic based studies also suggest that 
NMO is more common in non-white populations28,29. The geographic distribution of NMO 
may thus oppose that of MS28. The available literature is limited to several case reports and 
case series of the clinical manifestations of NMO.  
Storoni et al reported findings of atypical ON in patients of African or African-Caribbean 
backgrounds30. They found that this group of patients has a disproportionately higher 
representation within the neuromyelitis spectrum of disorders than Caucasian patients in the 
study population30. A high incidence of aquaporin-4 antibody (a marker for NMO) has been 
found in patients with isolated atypical ON28,32. NMO-seropositivity was shown to be a 
predictor of poor outcome28.  
Several studies have found a possible causal relationship between tuberculosis infection and 
NMO13,14. A review of 14 patients found an odds ratio of 4.6 for the presence of active TB 
versus the control group. A separate report also noted a close temporal relationship between 
pulmonary TB and the development of NMO and postulated that the mechanism was an 
immune reaction to tuberculosis.  
MS is uncommon in African populations with black Africans having the lowest prevalence of 
the disease. Studies looking at ON in African or Afro-Caribbean populations have found that 
the clinical presentation is more atypical, that there is a higher association with NMO 
spectrum disorders, and that these patients thus carry a more guarded visual prognosis 
compared to MS related ON28,31. 
Although accepted as distinct clinical entities there is some evidence that MS, NMO and 
other demyelinating conditions are part of a spectrum of disorders with a common 
pathogenetic mechanism31. Modi et al describe a series of cases of recurrent, remitting and 
relapsing demyelinating disease affecting black patients, with a female preponderance31. 
The cases showed a predominant clinical picture of NMO but had overlapping features of 
MS, NMO and ADEM31. 
3.5 Optic neuritis and HIV 
Sub-Saharan Africa carries approximately two thirds of the global burden of HIV infection 
with an estimated 25 million infected individuals32.  The overall prevalence of optic nerve 
disease in HIV ranges between 8% and 33% 33,34,35,36. The neurotropic nature of the virus 
has been attributed as a direct cause of optic neuropathy in the absence of opportunistic 
infection; however, opportunistic infections must first be ruled out as an aietiology. The most 
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common opportunistic agents are cryptococcus, toxoplasma, varicella, syphilis and 
cytomegalovirus37.  
Optic neuropathy can occur in any stage of the disease38. Case reports have described optic 
neuropathy as a primary presentation, and it may be part of the seroconversion illness 
37,39,40. A relapsing form of optic neuropathy similar to demyelinating disease has also been 
described41. There are several postulations about the pathophysiology of HIV optic 
neuropathy. 
HIV infection can cause a microangiopathy42. Endothelial cell dysfunction and the unchecked 
activation of the platelet cascade leads to microvascular occlusive disease42. The proposed 
mechanism is an ischaemic neuropathy. Non-arteriticischaemic optic neuropathy as a result 
of HIV infection,has been described in a young patient with no other vascular risk factors43. 
HIV has been shown to directly invade the optic nerve44,45. Post mortem analysis of optic 
nerves in HIV positive individuals has shown mononuclear cell infiltration with 
oligodendrocyte and myelin degeneration45. The resultant insult is a product of HIV induced 
macrophage activity with cellular damage occurring as a result of cytokine and tumor 
necrosis factor (TNF) alpha release rather than by direct invasion by HIV45. 
The neurotropic nature of HIV is well described46. The potential reservoir of virus in neuronal 
tissue leads to immune system dysfunction46. There is an increase in autoimmune markers 
during the seroconversion stage and then again during HAART therapy47. Multiple 
rheumatological conditions with an autoimmune basis have been described in patients 
during the above stages of viral infection47. There is thus a possible pathogenic role for an 
autoimmune based optic neuropathy particularly in recurrent or relapsing cases. 
Non-nucleoside reverse transcriptase inhibitors are potentially toxic to mitochondria resulting 
primarily in lactic acidosis48. The additional mitochondrial insult may cause optic neuropathy 
in patients with a predisposition such as Lebers hereditary optic neuropathy49. Toxic optic 
neuropathy is also more commonly seen in patients on ethambutol therapy and HAART50. 
The possible effect of these drugs as an aeitiology should be considered, particularly in 
patients with bilateral disease50. 
 
3.6 Treatment forOptic Neuritis 
The Optic Neuritis Study Group published the findings of the Final Report of the Optic 
Neuritis Treatment Trial in 200851. The data were based on a 15 year follow up of 389 
patients recruited into the study between 1988 and 199151. The study found that the greatest 
predictor of the development of ON was the presence of plaques on MRI scan51. The role of 
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corticosteroid therapy raised someimportant observations. High dose intravenous 
corticosteroids followed by a ten day oral tapering dose improved visual recovery time but 
had no effect on long term visual outcome versus placebo controls51. The use of oral 
corticosteroids seemed to increase the risk of a second neurological event in the first two 
years following treatment51. However this risk was not significant after two years51. A 
Cochrane review of the role of corticosteroid therapy has also found that steroids have no 
statistically proven benefit in terms of final visual outcome52. The vast majority of patients 
with typical ON have complete or near complete visual recovery following the initial 
episode51,52. The decision to treat patients with demyelinating ON with corticosteroids is 
dependent on the need for rapid visual recovery.  
In contrast, there is a higher incidence of atypical ON in African or Afro-Caribbean 
populations. Pokroy et al reported poorer visual outcomes in 18 eyes treated with steroid 
therapy with only six eyes achieving a vision of 6/12 or better at three month follow up17. A 
higher association of NMO as well as relapsing optic neuritis was found in patients of African 
or Caribbean descent30. Therefore, ethnicity, needs to be considered in the investigation and 
management of patients presenting with optic neuritis, particularly with atypical features30. 
Most American and European centres have protocols for the treatment of isolated idiopathic 
ON based on the ONTT, a policy which has been adapted to other countries with different 
ethnic profiles. The use of steroids may prove of benefit in cases of atypical ON in 
preventing retinal nerve fibre layer injury12. Although patients with atypical ON have poorer 
outcomes compared to typical demyelinating ON, steroids may play a role in halting disease 
progression9,30. Furthermore, it will identify patients with poor response to steroids, or 
relapsing cases who need to be considered for long term steroid sparing 
immunosuppressive therapy. 
Steroids have also been shown to have a benefit in both infectious and non-infectious 
inflammatory optic neuropathies53. Several case reports describe improvement in visual 
function following ON secondary to systemic lupus erythematosis, sarcoidosis and 
Wegeners granulomatosis54,55,56. These patients, however, required a longer steroid taper 
than that used in the ONTT and also required long term steroid sparing immunosuppressive 
therapy54,55,56. 
Steroids have also been used in conjunction with definitive treatment for infectious ON. 
Several case reports describe the use of steroid therapy in combination with anti-retroviral 
therapy for the treatment of HIV associated ON57,58,59.  
There is no clear consensus on the type and route of administration of steroid therapy. 
Several series have shown dexamethasone to be as effective as methylprednisone with the 
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added advantage of lower cost60. Omoti et al describe the effective use of sub-tenonsdepo-
methylprednisolone acetate, followed by oral prednisolone for the treatment of optic 
neuritis61. In the three reported cases all recovered visual acuity to 6/661. 
There is no randomized control trial looking at steroid versus placebo treatment for the 
treatment of AQP-4 positive isolated or atypical optic neuritis.  
3.7 Need for further research 
The clinical spectrum of optic neuritis in an African population group is not well described. 
Several studies mentioned above have confirmed the low prevalence of MS in Sub-Saharan 
Africa, yet the clinical profile, causes, and outcomes of ON in an African population has not 
been elucidated. The role of HIV and other infectious diseases impact on the presentation 
and outcome of optic neuritis is not well understood. 
The treatment of ON at Groote Schuur Hospital involves admission for baseline serological 
and imaging studies and treatment with intravenous methylprednisone, followed by tapering 
oral prednisone (as described in the ONTT). Patients of African lineage have a higher 
incidence of atypical ON and the effect of steroid therapy on disease progression has not 
been well established.  
This study aims to describe the clinical profile of ON presenting to the Groote Schuur 
Hospital ophthalmology unit, to describe the secondary causes of optic nerve 
inflammationand to determine the outcomes of ON. The findings of this study will allow one 
to assess the possibility of a treatment based study comparing various treatment arms 
versus placebo to determine whether steroid therapy is indeed beneficial for the treatment of 
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Clinical profile, causes,  and outcomes of optic neuritis at Groote Schuur Hospital 
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Introduction 
Optic neuritis is defined as an inflammatory condition of the optic nerve1. The aetiology can 
be divided into demyelinating, infectious, para-infectious and non-infective inflammatory 
disorders1. The most common cause of optic neuritis worldwide is demyelinating disease, 
and in countries where multiple sclerosis is common, this accounts for the majority of 
cases1,2,3. In the United States the incidence of optic neuritis is approximately 5/100 000, 
which closely follows the incidence of multiple sclerosis1,2,3. Optic neuritis is most commonly 
unilateral and tends to affect females more than males1,2,3. The optic neuritis treatment trial 
identified those features which had a higher association with the development of multiple 
sclerosis giving rise to the term “typical optic neuritis”4. The features of typical optic neuritis 
include acute vision loss over two weeks with recovery by four to six weeks, pain on extra-
ocular movement, age between 15-45 years, unilateral involvement, and no other systemic 
illness to account for the symptoms1.  
In contrast African populations tend to have more atypical presentations of optic neuritis and 
a lower prevalence of multiple sclerosis5,6. Limited information is available on the clinical 
profile, causes and outcomes of optic neuritis in African populations. We describe the clinical 
profile, causes and outcomes of cases admitted to the Groote Schuur Hospital with optic 
neuritis. 
Methods 
A retrospective analysis of 117 case records of patients admitted to Groote Schuur Hospital 
and treated for optic neuritis between January 2002 and December 2012 was conducted. 
Inclusion criteria were based on clinical findings of acute optic nerve dysfunction with or 
without optic disc swelling. Acute optic nerve dysfunction was defined by the following 
clinical signs; visual loss, presence of an afferent papillary defect, dyschromatopsia 
(objectively measured using Ishihara test plates edition 7) and decreased light brightness 
appreciation. All patients admitted with acute optic nerve dysfunction were investigated with 
serological tests, chest x-rays (to help exclude sarcoid and tuberculosis), imaging in the form 
of a contrasted CT scan and cerebro-spinal fluid (CSF) analysis if no contra-indication to 
lumbar puncture were present. Serological tests performed were aimed at excluding 
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systemic conditions known to be associated with optic neuritis, thus an auto-immune screen 
(rheumatoid factor, ANA, c and p ANCA, anti ds-DNA and anti-phospholipid antibody), 
serum angiotensin converting enzyme, HIV serology, serum RPR and FTA, erythrocyte 
sedimentation rate and full blood count with differential was conducted. All patients admitted 
for optic neuritis were treated with systemic steroids in the form of 3 days of intravenous 
methylprednisone (1gm daily), followed by 10 days of 1mg/kg oral prednisone. NMO 
antibody testing was not available during the study period. Demographic information, clinical 
presentation, course of illness, investigations performed and visual outcomes at discharge 
and at three month follow up were collected. Patients who had positive serological tests, 
chest x-rays, CSF analysis or abnormalities of neuro-imaging suggestive of a possible 
secondary cause were labeled as having secondary optic neuritis. Treatment for the 
secondary cause was instituted as appropriate. Patients who had negative serology, chest x-
rays, neuro-imaging and CSF analysis were labeled as having idiopathic optic neuritis. The 
idiopathic groups were then sub-divided as being atypical or typical. Atypical optic neuritis 
was defined as having any one of the following clinical criteria; profound vision loss (worse 
than count fingers vision), visual loss of 3 or more weeks with no improvement, bilateral 
involvement, absence of pain and age >50 years or < 12years. The data was collated in an 
excel spreadsheet and then analysed using STATA version 10.0.Wilcoxon-Mann Whitney 
rank-sum test was used to test significance of associations. Logistic regression analysis was 
also used to test significance in multivariate analysis. 
Ethical approval for the study was obtained from the Human research and ethics committee 
of the University of Cape Town. 
 
Results 
Figure one shows the numbers of secondary and idiopathic optic neuritis, and the numbers 
of idiopathic optic neuritis with typical and atypical features. 
Figure two shows the causes of secondary optic neuritis. 
Table one shows the demographic and clinical profile of secondary and idiopathic optic 
neuritis. 
Table two shows the outcomes at discharge and 3 month follow up of secondary and 
idiopathic optic neuritis. 
Patients with secondary optic neuritis and idiopathic atypical optic neuritis with a presenting 
visual acuity (VA) of HM or worse had a poorer outcome at follow up (mean VA =1.53 
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LogMAR vs 0.81 LogMAR, p = 0.015) compared to patients with better than HM presenting 
vision in the same group. 
There were four cases (4 of 117) in which the CT scan was abnormal. Two had a pituitary 
tumour, one had a tuberculous granuloma and one had non-specific cerebral atrophy. MRI 
was only performed for patients in whom there was a high index of suspicion for 
demyelination, thus the majority of MRI scans were performed on patients with typical optic 
neuritis.13 of 20 MRI scans (11 performed for patients with typical ON and 2 for idiopathic 
atypical ON) were abnormal, with the predominant finding being areas of non-specific white 
matter abnormal signal, possibly indicating demyelination. Serum angiotensin converting 
enzyme, full blood count and erythrocyte sedimentation rate were normal in all cases. The 
only blood investigations that yielded positive results were the HIV (28 cases) and serum 
FTA  (12 cases). Lumbar puncture was performed in 90 of 117 cases. 70 of the 90 cases 
yielded normal CSF findings. The predominant finding in abnormal lumbar punctures was a 
mild leukocytosis with normal total protein (15 cases). Three cases demonstrated 
cryptococcal meningitis (CCM), one was cytomegalovirus PCR positive and one was 
varicella zoster PCR positive. In these patients visual loss from optic nerve inflammation was 
the presenting feature of their disease. 
No difference in mean VA at 3 month follow up was demonstrated for unilateral vs bilateral 
disease or for the presence of disc swelling at presentation in any of the 3 subgroups 
analysed.  
Of the 14 patients with typical optic neuritis four patients went on to develop possible 
multiple sclerosis (three of mixed descent and one Indian), and one white patient had 












Fure 1. Numbers of secondary and idiopathic optic neuritis, and idiopathic optic 
neuritis with typical or atypical features 
 
 
Figure 2. Causes of secondary optic neuritis 
(CCM = cryptococcal meningitis, TB = tuberculosis, ADEM = acute demyelinating 
encephalomyelitis, Toxo = toxoplasmosis, CMV = cytomegalovirus, VZV = varicella zoster) 
 
 








HIV Syphilis CCM TB ADEM Toxo CMV VZV
% 
      Secondary  Idiopathic  atypical 
Idiopathic 
typical 
Number     60   43   14   
Age              
  Mean 
 
36.34   40   35.36   
  Median 
 
35   39   32   
  Min 
 






Table 2. Outcomes of secondary and idiopathic optic neuritis 
      Secondary 
Idiopathic 
atypical Idiopathic typical 
                  
VA at discharge 
(LogMAR)               
  Mean 
 
1.38 (+/- 1.14)   1.44 (+/-1.16)   0.36 (+/-0.51) 
  Median 
 
0.9    1.4     0.2    
  Min 
 
0   -0.1   0   
  Max   4   4   2   
  Max   79   62   52   
Gender             
  Male  
 
23   13   11   
  Female   37   27   3   
Race                 
  Black African  40   18   1   
  Caucasian 
 
3   2   2   
  Mixed ethnic 
 
16   18   10   
  Indian / asian   1   5   1   
Papillitis   40   23   8   
Bilateral     27   12   0   
Pain on EOM   18   10   14   
Time from onset to presentation (days)           
  Mean 
 
15.06    8.35   10.64   
  Median 
 
7    7   7   
  Min 
 
1    1   1   
  Max   168    28   56   
Presenting VA (LogMAR)            
  Mean 
 
2.2   2.35   1.05   
  Median 
 
2   2.5   0.9   
  Min 
 
0.2   0.2   0.2   
  Max   4   4   2   
Presenting Ishihara (score 
out of 14) 
 
       
 
  
  Mean 
 
1.4   0.5   5   
  Median 
 
0   0   1   
  Min 
 
0   0   0   
  Max   14   12   12   
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VA at 3month follow-up 
(LogMAR)             
  Mean 
 
1.34 (+/- 1.26)   1 (+/- 1.17)   0.23 (+/- 0.52)   
  Median 
 
1    0.3    0.1   
  Min 
 
-0.1   -0.1   -0.1   
  Max   4   4   2   
Ishihara at discharge             
  Mean 
 
3.06 (+/-4.97)   4 (+/-5.09)   10.5 (+/-3.93)   
  Median 
 
0   0   12   
  Min 
 
0   0   0   
  Max   0   14   14   
Ishihara at 3month 
follow-up         
 
  
  Mean 
 
4.68(+/-5.8)   6.6(+/-6.09)   12.14(+/-3.7)   
  Median 
 
0   5   13.5   
  Min 
 
0   0   0   
  Max   14   14   14   
 
Discussion 
Optic neuritis in the study population differs from that reported in Europe and the United 
States with the majority of patients either having a secondary cause or having atypical 
features.  
38(69%)  of 55  patients with secondary optic neuritis tested for HIV were positive. Absence 
of pain and optic disc swelling are more common features of optic neuritis in the study group. 
In the idiopathic  atypical group, the absence of pain, profound visual loss and bilateral 
disease are the main clinical features deviating from the typical features of the optic neuritis 
treatment trial (ONTT). 4 
Pokroy et al looked at the clinical profile of cases of idiopathic optic neuritis in black patients 
and their response to treatment.6 In contrast to the ONTT they found that of the 10 patients 
in their study, the majority had bilateral consecutive or simultaneous disease and 15 out of 
the 18 eyes had optic disc swelling.4,6 Black patients had a poorer visual prognosis 
compared to the patients in the ONTT.4,6 The review did not look at secondary causes of 
optic neuritis in black patients. Idiopathic optic neuritis in our study population is 
predominantly atypical, in keeping with these findings. 
Similar findings of atypical optic neuritis are reported in patients of African or African-
Carribean backgrounds.5 This group of patients had a disproportionately higher 
representation within the neuromyelitis spectrum of disorders than caucasian patients in the 
study population.5 Several studies have further shown a high incidence of aquaporin-4 
antibody (a marker for neuromyelitis optica) amongst patients with isolated atypical optic 
35 
 
neuritis.5,7,8Neuromyelitisopticaseropositivity was shown to be a predictor of poor 
outcome.5,7,8 
There are several studies which have tried to identify the multiple sclerosis rates in South 
Africa. Dean et al reported an incidence of 13/100 000 in English speaking whites with no 
cases reported in black patients9. In a follow up study in 1994, only six cases of possible 
multiple sclerosis in black South Africans was found10. A study on crude prevalence data in 
the Kwazulu-Natal province of South Africa found a prevalence of 25.63/100 000 in whites, 
0.99/100 000 in blacks, and 1.94/100 000 in people of mixed descent11. All of these studies 
seem to confirm that multiple sclerosis in black and mixed ancestry people is uncommon. 
Although the study population is small and the time frame not long enough, our study seems 
to also suggest that demyelinating optic neuritis associated with MS is uncommon in black 
patients. 
The ONTT identified risk factors predicting multiple sclerosis associated optic neuritis4. The 
identification of these features helped to identify cases in which extensive investigation 
would prove unhelpful and therefore unnecessary 2. In our study 4 of the CT scans 
performed revealed unusual causes of acute optic nerve dysfunction. 2 cases revealed a 
pituitary adenoma (with compressive optic neuropathy), 1 tuberculous granuloma and 1 
generalized cerebral atrophy (thought to be part of advanced HIV disease). Both cases of 
pituitary adenoma and the tuberculous granuloma showed an initial response to steroid 
treatment. The cases of pituitary adenoma were referred to neurosurgical services and anti-
tuberculous therapy was initiated in the patient with a tuberculous granuloma. Our study 
population has a high proportion of secondary and atypical idiopathic optic neuritis, and thus 
African patients with optic neuritis require thorough investigation for causes other than 
demyelinating disease as this may influence treatment. 
The ONTT as well as meta-analyses of 12 randomised control trials revealed that 
corticosteroid therapy significantly improved short term visual acuity recovery but had no 
statistically significant effect on long term visual outcome.2,4 Furthermore the natural course 
of MS related optic neuritis is recovery of visual function even without therapy. The clinical 
experience at Groote Schuur Hospital is that the majority of patients do not fit the typical 
profile of the ONTT. Furthermore the HIV epidemic confounds the clinical picture both due to 
the neurotropic nature of the virus, and associated opportunistic infections. Steroid therapy 
may play a more important role in treating optic nerve inflammation(in combination with the 
appropriate treatment for identified secondary causes), and preventing permanent visual 
loss in African patients with optic neuritis, where the multiple sclerosis incidence is low. 
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The secondary, idiopathic atypical and idiopathic typical optic neuritis groups all seemed to 
show some improvement of visual acuity with steroid therapy. Gains in visual acuity were 
most pronounced in the idiopathic typical group, in keeping with demyelinating optic neuritis.. 
A small case series describes the use of subtenons steroid for the treatment of optic neuritis 
in black patients with good clinical response12. Studies on the use of dexamethasone in 
Indian populations have also shown good response to therapy13.   
Conclusion 
Optic neuritis in  African populations, with a low prevalence of multiple sclerosis, tends to be 
atypical in presentation, with a high proportion of patients having an identifiable secondary, 
most commonly infectious cause. In settings with a high HIV prevalence, HIV and syphilis 
testing should form part of the routine first line investigations for patients presenting with 
optic neuritis. Thorough investigation for possible secondary causes should be undertaken 
as these may influence management.  Secondary optic neuritis and idiopathic atypical optic 
neuritis carry a poorer prognosis than typical demyelinating optic neuritis.. A weakness of 
our study is that it is a retrospective case note review. A prospective study to assess various 
regimens of steroid therapy, and the role of neuromyelitis optica serology in our patients 
would be helpful.  
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(NLM) articles that require deposit and will transmit the post-print of an article based on 
research funded in whole or in part by the National Institutes of Health, Wellcome Trust, 
Howard Hughes Medical Institute, or other funding agencies to PubMed Central. The revised 
Copyright Transfer Agreement provides the mechanism.  
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Copyright Transfer Agreement. This is a form that requires the signature of all authors. It 
is available on the journal’s online submission system or by e-mailing the editorial office at 
jneuroophthalmol@gmail.com. It must be submitted with the manuscript. A manuscript 
cannot be published until the editorial office has received this form. Failure to return this 
form will result in a delay in the publication of your manuscript. 
Permissions: Authors must submit written permission from the copyright owner (usually the 
publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted 
form elsewhere, along with complete details about the source.  
Types of submissions 
Editorials: commissioned commentaries on matters published in that Journal issue. No 
abstract.  
Original contributions: clinical investigations, basic science experiments or case reports. For 
clinical and basic science articles a structured abstract is required and the text is limited to 
2,500 words. It should contain four headings: background, methods, results, and conclusion. 
The text should begin with an introduction followed by three headings: methods, results, 
conclusions. For case reports, an unstructured abstract is required. Following an 
introduction, the text should contain two headings: case report, discussion and should not 
exceed 2,000 words.  
Photo essay: Observations based on interesting or unusual images. Use of the latest 
imaging techniques is encouraged. Unstructured abstract. Text is limited to 900 words and 
should contain no introduction. Begin with a case description followed by an interpretation of 
the findings.  
State-of-the-Art Review: articles that bring together and analyze the significance of material 
on one or two topics. These are usually solicited but unsolicited material will be considered. 
Please contact the editor-in-chief before writing a review article for the Journal. Structured 
abstract is required and should have four headings: background, evidence acquisition, 
results, conclusions. The text is limited to 3,000 words.  
The Hoyt Lecture: a modified version of the lecture delivered at the annual meeting of the 
American Academy of Ophthalmology.  
The Jacobson Lecture: a modified version of the lecture delivered at the annual meeting of 
the North American Neuro-ophthalmology Society.  
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Point Counter-point: Laboratory investigations in experimental neuro-ophthalmology. A 
structured abstract of 250 words or less is required and should contain four headings: 
introduction, methods, results, and conclusion. The text is limited to 3,000 words. It should 
begin with an introduction followed by three headings: methods, results, conclusions.  
Basic and Translational Research: Laboratory investigations in experimental neuro-
ophthalmology. A structured abstract of 250 words or less is required and should contain 
four headings: introduction, methods, results, and conclusion. The text is limited to 3,000 
words. It should begin with an introduction followed by three headings: methods, results, 
conclusions.  
Literature Commentary: commissioned discussion of articles published elsewhere in the 
literature that are of importance to the readership of the Journal of Neuro-ophthalmology. 
Clinical-pathological case (CPC) study: commissioned case studies presented in a 
prescribed format of a CPC: clinical history and examination findings, differential diagnosis, 
neuroimaging results, pathological findings, final diagnosis.  
Clinical Observations: cases of less rigor than a case report. Unstructured abstract. 
Books Received: a brief description of recent publications of interest to the readership of the 
Journal.  
Letters to the Editor: readers’ comments on previously published articles in the Journal. 
Neuro-ophthalmology News: commissioned material updating the readership on news and 
events in the field of neuro-ophthalmology.  
Preparation and Submission of the Manuscript 
The journal now requires ALL manuscripts and illustrations to be submitted via our online 
submission site at http://www.editorialmanager.com/jno. We will NOT accept hard copy 
manuscript submission or submissions received by email or CD.  
General format: All manuscripts must be submitted in English. Double-space all copy and 
include a running 
title. Please clearly label every file name to correspond with content (e.g Main Manuscript, 
Figure 1; Table 1, etc)  
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Title page:  
Include:  
 complete manuscript title 
 running title (to be included at top of the page) 
 full author names 
 academic degrees (eg PhD, MD) 
 affiliations of all authors including city and country 
 postal address, e-mail address and telephone number of the corresponding author 
 conflict of interest statement (if there is no Conflict to disclosure, please state so on 
the title page) 
 3-6 keywords 
 disclosure of any funding received for this work - Please clearly identify if your 
research was funded from any of the following organizations: National Institutes of 
Health (NIH); Wellcome Trust; Howard Hughes Medical Institute (HHMI); and other(s) 
Please specify if the corresponding author is different from the author who is to receive 
reprints.  
Abstract:  
Please refer to the Types of Submission section (above) for information on the correct 
Abstract format to be used based upon the type of article to be submitted. 
Text: For headings inside the manuscript please refer to the Types of Submission section 
above.  
Define abbreviations at first mention in text and in each table and figure. If a brand name is 
cited, supply the manufacturer’s name and address (city and state/country). 
Abbreviations: For a list of standard abbreviations, consult the Council of Science Editors 
Style Guide (available from the Council of Science Editors, 9650 Rockville Pike, Bethesda, 
MD 20814) or other standard sources. Write out the full term for each abbreviation at its first 
use unless it is a standard unit of measure. 
References: Authors are responsible for the accuracy of the references. Key the references 
(double-spaced) at the end of the manuscript. Cite the references in text in the order of 
appearance. Cite unpublished data, such as papers submitted but not yet accepted for 
publication or personal communications, in parentheses in the text. Please include ALL 
author names in your citation – using et al after the first three authors is not 
acceptable. Refer to the List of Journals Indexed in Index Medicus for abbreviations of 
journal names, or access the list at http://www.nlm.nih.gov/tsd/serials/lji.html. Sample 
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references are given below: 
Journal article 
1. Manrique RK, Noval S, Aguilar-Amat MJ, Arpa J, Rosa I, Contreras I. Ophthalmic features 
of spinocerebellar ataxia type 7. J Neuroophthalmol. 2009; 29:174-179 
Book chapter 
2. Todd VR. Visual information analysis: frame of reference for visual perception. In: Kramer 
P, Hinojosa J, 
eds. Frames of Reference for Pediatric Occupational Therapy. Philadelphia: Lippincott 
Williams & Wilkins, 
1999:205–256. 
Entire book 
3. Glaser JS. Neuro-Ophthalmology, 3rd edition. Philadelphia: Lippincott Williams & Wilkins, 
1999. 
Software 
4. Epi Info [computer program]. Version 6. Atlanta: Centers for Disease Control and 
Prevention; 1994. 
Online journal 
5. Miyamoto O, Auer RN. Hypoxia, hyperoxia, ischemia, and brain necrosis. Neurology 
[serial online] 
2000;54:362–371. Available at: www.neurology.org. Accessed February 23, 2000. 
Database 
6.CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. 
Updated March 29, 
1996. 
World Wide Web 
7.Gostin LO.Drug use and HIV/AIDS [JAMA HIV/AIDS web site]. June 1, 1996. Available at: 
http://www.ama-assn.org/special/hiv/ethics. Accessed June 26, 1997. 
Figures. 
The Journal of Neuro-Ophthalmology has strict guidelines on image quality. You must 
ensure your figures follow these rules. Failure to supply files in the format specified below 
will result in the images being returned to you for re-formatting. This may lead to an 
associated delay in the review and publication of your manuscript. 
o Artwork saved as TIF or EPS files. PowerPoint files are also acceptable for line art (if 
your graph was generated in PowerPoint). Presentation slides are NOT acceptable 
as figures. 
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o Crop out any white or black space surrounding the image.
o Text and fonts in any figure must be one of these acceptable fonts: Helvetica, Times
Roman, Symbol, Mathematical PI, and European PI.
o Do not include label identification (e.g. Figure 1A) within the image. Please identify
the figure title in your figure legend.
o Color images are created/scanned and saved and submitted as CMYK only. Do not
submit any figures in RGB mode.
o Line art saved at a resolution of at least 1200 dpi.
o Color and half-tone images must be saved at a resolution of at least 300 dpi.
o Each figure saved as a separate file and saved separately from the accompanying
text file.
o Each figure file must be saved with the title of the figure in the file name. e.g. Figure
1A.tif; Figure 1B.eps
Remember: 
o Artwork generated from office suite programs such as CorelDRAW and MS Word,
and artwork downloaded from the Internet (JPEG or GIF files) cannot be used
because the quality is poor when printed.
o Cite figures consecutively in your manuscript.
o Number figures in the figure legend in the order in which they are discussed.
o Upload figures consecutively to the Editorial Manager web site and number figures
consecutively in the Description box during upload
o Please do not upload images of tables. All tabular matter must be editable. An image
of a table, such as a scan, is not acceptable for publication.
Please do not include images within your manuscript MS Word document. You must 
also not provide images in individual word document files. By doing so, the quality of 
the image is reduced and is not acceptable for publication. All images must be 
uploaded as individual files in TIF or EPS file formats. 
Color figures: Authors may choose to pay to publish color figures in the print issue of the 
journal. There is a per figure charge for color. The price for the first color figure is $650. The 
charge for each additional color figure is $100. At the proof stage, authors will be given the 
option to choose to pay for color in print. If an author does not want to pay for color, authors 
should request that the figures be converted to black and white at no charge. All color figures 
will appear in the online version of the article at no cost to the author.  
45 
 
Figure legends: Legends must be submitted for all figures. They should be brief and 
specific and appear on 
a separate manuscript page after the references. Each legend should begin with a brief 
statement that identifies the figure. (Examples: Magnetic resonance imaging, Case 1; or 
Multifocalelectroretinogram, Case 
2; or Biopsy of left upper lid, Case 3.) Use scale markers in the image for electron 
micrographs and indicate the type of stain used for tissue.  
Tables: Please do not upload images of tables. All tabular matter must be editable. An 
image of a table, such as a scan, is not acceptable for publication.  
Supplemental Digital Content:  
Authors may submit SDC via Editorial Manager to LWW journals that enhance their article's 
text to be considered for online posting. SDC may include standard media such as text 
documents, graphs, audio, video, etc. On the Attach Files page of the submission process, 
please select Supplemental Audio, Video, or Data for your uploaded file as the Submission 
Item. If an article with SDC is accepted, our production staff will create a URL with the SDC 
file. The URL will be placed in the call-out within the article. SDC files are not copy-edited by 
LWW staff, they will be presented digitally as submitted. For a list of all available file types 
and detailed instructions, please visit http://links.lww.com/A142. 
Supplemental Digital Content Size & File Type Requirements: To ensure a quality 
experience for those viewing supplemental digital content, it is suggested that authors 
submit supplemental digital files no larger than 10 MB each. Documents, graphs, and tables 
may be presented in any format. Figures, graphics, and illustrations should be submitted 
with the following file extensions: .tif, .eps, .ppt, .jpg, .pdf, .gif. Audio files should be 
submitted with the following file extensions: .mp3, .wma. Video files should be submitted with 
the following file extensions: .wmv, .mov, .qt, .mpg, .mpeg, .mp4. Video files should also be 
formatted with a 320 
X 240 pixel minimum screen size. For more information, please review LWW’s requirements 
for submitting supplemental digital content: http://links.lww.com/A142 
Style: Pattern manuscript style after the American Medical Association Manual of Style (9th 
edition). 
Stedman's Medical Dictionary (27th edition) and Merriam Webster's Collegiate Dictionary 
(10th edition) should be used as standard references. Refer to drugs and therapeutic agents 
by their accepted generic or chemical names, and do not abbreviate them. Use code 
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numbers only when a generic name is not yet available. In that case, supply the chemical 
name and a figure giving the chemical structure of the drug. 
Capitalize the trade names of drugs and place them in parentheses after the generic names. 
To comply with trademark law, include the name and location (city and state in USA; city and 
country outside USA) of the manufacturer of any equipment mentioned in the manuscript. 
Use the metric system to express units of measure and degrees Celsius to express 
temperatures, and use SI units rather than conventional units.  
AFTER ACCEPTANCE 
Electronic page proofs and corrections: Corresponding authors will receive electronic page 
proofs to check the copyedited and typeset article before publication. Portable document 
format (PDF) files of the typeset pages and support documents (such as the reprint order 
form) will be sent to the corresponding author via email. 
Complete instructions will be provided with the e-mail for downloading and printing the files 
and for faxing the corrected pages to the publisher.  
It is the author's responsibility to ensure that there are no errors in the proofs. Changes that 
have been made to conform to Journal style should be allowed to stand if they do not alter 
meaning. Authors may be charged for alterations to the proofs beyond those required to 
correct errors or to answer queries. Electronic proofs must be checked carefully and 
corrections faxed within 24 to 48 hours of receipt, as requested in the electronic cover letter 
accompanying the page proofs.  
Open access 
LWW’s hybrid open access option is offered to authors whose articles have been accepted 
for publication. With this choice, articles are made freely available online immediately upon 
publication. Authors may take advantage of the open access option at the point of 
acceptance to ensure that this choice has no influence on the peer review and acceptance 
process. These articles are subject to the journal’s standard peer-review process and will be 
accepted or rejected based on their own merit.  
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual 
unrestricted online access to their published article to readers globally, immediately upon 
publication. The article processing charge for Neuro-Ophthalmology is $2,500. The article 
processing charge for authors funded by the Research Councils UK (RCUK) is $3,175. The 
publication fee is charged on acceptance of the article and should be paid within 30 days by 
credit card by the author, funding agency or institution. Payment must be received in full for 
the article to be published open access.  
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Authors retain copyright 
Authors retain their copyright for all articles they opt to publish open access. Authors grant 
LWW a license to publish the article and identify itself as the original publisher.  
Creative Commons license 
Articles opting for open access will be freely available to read, download and share from the 
time of publication. Articles are published under the terms of the Creative Commons License 
Attribution-NonCommerical No Derivative 3.0 which allows readers to disseminate and reuse 
the article, as well as share and reuse of the scientific material. It does not permit 
commercial exploitation or the creation of derivative works without specific permission. To 
view a copy of this license visit: http://creativecommons.org/licenses/by-nc-nd/3.0.  
Compliance with NIH, RCUK and other research funding agency accessibility 
requirements 
A number of research funding agencies now require or request authors to submit the post-
print (the article after peer review and acceptance but not the final published article) to a 
repository that is accessible online by all without charge. As a service to our authors, LWW 
identifies to the National Library of Medicine (NLM) articles that require deposit and transmits 
the post-print of an article based on research funded in whole or in part by the National 
Institutes of Health, Howard Hughes Medical Institute, or other funding agencies to PubMed 
Central. The revised Copyright Transfer Agreement provides the mechanism. LWW ensures 
that authors can fully comply with the public access requirements of major funding bodies 
worldwide. Additionally, all authors who choose the open access option will have their final 
published article deposited into PubMed Central. RCUK funded authors can choose to 
publish their paper as open access with the payment of an article process charge, or opt for 
their accepted manuscript to be deposited (green route) into PMC with an embargo.  
With both the gold and green open access options, the author will continue to sign the 
Copyright Transfer Agreement (CTA) as it provides the mechanism for LWW to ensure that 
the author is fully compliant with the requirements. After signature of the CTA, the author will 
then sign a License to Publish where they will then own the copyright. It is the responsibility 
of the author to inform the Editorial Office and/or LWW that they have RCUK funding. LWW 
will not be held responsible for retroactive deposits to PMC if the author has not completed 
the proper forms.  
FAQ for open access 
http://links.lww.com/LWW-ES/A48 
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Folder No.   
Age               
Gender  1= female 
2= male 
Race  1= Black 
2= White 
3= Mixed race 
4= Indian / asian 
Ocular disease      1=Yes 
2= No 
Systemic disease      1= Yes 
2= No 
Uni / Bilateral      1= Unilateral 
2= Bilateral 
Optic disc swelling  1= yes 
2= no 
Time from onset to 
presentation (days)     
  









Ishihara at presentation 
Right 
  
Ishihara at presentation 
Left 
  
Pain on eye movement      1 = yes 
2= no 
Brightness score Right   
Brightness score Left   
RAPD and grade       
Visual field defect   1=Centrocaecalscotoma 
2 = enlarged blind spot 
3 = total filed loss 
4 = other 
CT findings     
 
 1 = Normal 
2= abnormal 
MRI findings     
 

















 1= normal 
2= abnormal 
Secondary diagnosis    
 
  
Visual acuity at 
discharge  Right 
  
Visual acuity at 
discharge  Left 
  
Ishihara score at 
discharge Right 
  
Ishihara score at 
discharge Left 
  
Brightness score at 
discharge    Right 
  
Brightness score at 
discharge    Left 
  
Visual acuity at 1st 




Right    
Visual acuity at 1st 
follow up & time (weeks) 
Left    
  
Ishihara score at 1st 
follow up   Right  
  
Ishihara score at 1st 
follow up    Left 
  
Brightness score at 1st 
follow up    Right 
  
Brightness score at 1st 
follow up    Left 
  
Visual acuity at last 
follow up & time (weeks) 
Right     
  
Visual acuity at last 
follow up & time (weeks) 
Left    
  
Brightness score at last 
follow up Right 
 
  
Brightness score at last 
follow up Left 
  
Ishihara score at last   
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follow up Right 
Ishihara score at last 























Appendix 2. Department of surgery research committee approval 
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Appendix 3. Human research ethics committee approval
